Staphylococcus epidermidis Persister Cell Elimination Using an Antimicrobial Peptide

Research Article

J Bacteriol Mycol. 2019; 6(2): 1101.

Staphylococcus epidermidis Persister Cell Elimination Using an Antimicrobial Peptide

Pihl M and Andersson M*

Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Sweden

*Corresponding author: Martin Andersson, Department of Chemistry and Chemical Engineering, Chalmers University of Technology, Kemivägen 10, SE- 412 96 Göteborg, Sweden

Received: February 13, 2019; Accepted: March 28, 2019; Published: April 04, 2019

Abstract

Biomaterial associated infections are often caused by Staphylococcus epidermidis, which is an opportunistic pathogen with the ability to form biofilms. Such biofilms are inherently resistant to antimicrobials, depending on a variety of factors, including presence of persister cells. Persister cells are dormant, non or slow growing, bacteria that survive long exposures of antibiotics. As an alternative to antibiotics, persisters may be killed using antimicrobial peptides (AMPs). The AMP RRP9W4N was evaluated with the objective to kill both planktonic and biofilm S. epidermidis persister and normal cells. Agar plating and colony counts in addition to fluorescence microscopy were used to determine bacterial survival after exposure to 0-200 μM of the AMP. Scanning electron microscopy was used for morphological bacterial studies. It was demonstrated that 200 μM of the antimicrobial peptide resulted in total planktonic persister elimination and collapse of biofilms, with swelling and bursting of bacteria. Interestingly, persisters seemed more susceptible towards the AMP compared to normal bacteria, another factor underlining the potential use of antimicrobial peptides in future clinical applications.

Keywords: Planktonic bacteria; Biofilm; Dormant; Ciprofloxacin; RP62A

Introduction

The risk of receiving an orthopaedic device-related infection is around 2% [1] and it is an increasing health care problem. In 2009, 566 million USD were spent in the US alone to treat 22’000 infected hip and knee implants, figures that are estimated to reach a cost of 1.62 billion USD in 2020 due to an aging population [2]. One of the most common causes of biomaterial associated infections is the human commensal bacterium Staphylococcus epidermidis and its major pathogenicity factor is related to its ability to form biofilms [3]. Finding new ways to eradicate this opportunistic pathogen is thus of vast importance.

Biofilm formation, extracellular polymer encapsulated bacterial growth on a surface, is causing 80% of all infections [4] and is of great concern when it comes to infection control. Biofilms are inherently resistant to antimicrobials and can be up to 1000 times more resistant to antibiotics compared to their corresponding planktonic counterparts. Biofilm resistance may be caused by different factors such as restricted penetration of the drug through the biofilm, antimicrobial destroying enzymes, efflux pumps, slow growth rate and presence of persister cells [5]. Persister cells are dormant, slow or non-growing, bacteria, which survive prolonged antibiotic treatments. Persisters enriched from a normal population using antibiotics produce a population indistinguishable from the original one with same antibiotic susceptibility, upon regrowth in fresh medium [6]. This indicates persistence is a phenotypic tolerance and not a genetic resistance. Persisters are likely responsible for recurrent biofilm associated infections [7] and antibiotics are usually not efficient in eliminating persisters as they generally act on dividing cells. Hence, new methods to eliminate bacteria, regardless of their metabolic activity, are needed. One possibility is the use of antimicrobial peptides, AMPs. By cleaving peptides from the protein PRELP (proline arginine-rich end leucine-rich repeat protein) and attaching a hydrophobic tail of tryptophan a proteolytically stable peptide with low toxicity for human cells and high bactericidal effect has been obtained, RRP9W4N [8]. This peptide it is active even against multiresistant bacterial strains of Staphylococcus aureus, Group A streptococci, Escherichia coli and Pseudomonas aeruginosa [8].

In this study, we enriched Staphylococcus epidermidis persister cells, both in planktonic and biofilm cultures. Then we investigated the ability of eliminating persisters using the antimicrobial peptide RRP9W4N, using agar plating with bacterial counts and microscopy with LIVE/DEAD staining. Bacterial morphology was investigated using scanning electron microscopy.

Material and Methods

Determination of minimum inhibitory concentration

Staphylococcus epidermidis ATCC 35984 (also known as RP62A) was cultured on Brain Heart Infusion (BHI) agar, 37°C overnight, and then 1 colony was cultured overnight (37°C) in Tryptic Soy Broth (TSB) until mid exponential phase and harvested by centrifugation (2500 rpm, 10 min). The formed pellet was resuspended in fresh TSB and distributed to serially diluted Ciprofloxacin, with final concentrations ranging from 0.03 mg/L to 8 mg/L and a final bacterial concentration of 5*105 CFU/ml. Bacteria were cultured for 24 hours (37°C) before visually inspected for bacterial growth, to determine the minimum inhibitory concentration, MIC. Three independent experiments were performed.

Planktonic persister enrichment

To investigate the proportion of persister cells, one colony of S. epidermidis 35984, obtained from BHI agar, was cultured overnight (37°C) in TSB until stationary phase, harvested by centrifugation (2500 rpm, 10 min) and resuspended in fresh TSB. In total volumes of 4 ml, antibiotic and bacteria were mixed to final concentrations of 2*105 CFU/ml and 0.25, 2.5, 5 and 25 mg/L Ciprofloxacin. Bacteria were cultured for 24 h, 37°C, before serially diluted and cultured on BHI agar plates, to determine CFU/ml. Three independent experiments were performed.

Planktonic bacterial elimination using an antimicrobial peptide

One colony of normal planktonic S. epidermidis 35984, obtained from BHI agar, was cultured overnight (37°C) in TSB until stationary phase and then harvested by centrifugation (2500 rpm, 10 min) and resuspended in fresh TSB. For persister cell enrichment, planktonic bacteria were cultured as above and then exposed to 5 mg/L Ciprofloxacin for 24 h, 37°C, before centrifugation (2500 rpm, 10 min) and resuspension in fresh TSB.

To investigate the antimicrobial effect on normal contra persister cells, they were subjected to an increasing concentration of the antimicrobial peptide RRPRPRPRPWWWW-NH2, RRP9W4N, (Bio-Peptide Ltd). Bacteria were subjected to 0, 25, 50, 100 or 200 μM AMP and cultured for 2 or 24 h (37°C) before serially diluted and cultured on agar plates.

Three independent experiments were made. Statistical analysis was performed using a one-way ANOVA with a Bonferroni post test and P value <0.05 was considered significant.

Biofilm persister enrichment

For biofilm persister cell enrichment, normal bacteria, which were produced as for planktonic bacterial elimination using an AMP, were cultured for 3 h in 8-well glass bottom μ-slides (Ibidi) and then the bacterial solutions were discarded. Biofilms were subjected to fresh medium containing 0, 0.25, 2.5, 5 or 25 mg/L Ciprofloxacin for 24 hours, 37°C, before washed twice in PBS and stained by LIVE/DEAD BacLight (Thermo Fisher Scientific) and studied in a fluorescence widefield microscope (Zeiss). Area covered by dead (red) or live (green) bacteria were evaluated using ImageJ [9]. Three independent experiments were performed.

AMP elimination of biofilm bacteria

Bacteria were cultured as for planktonic bacterial elimination using the AMP. Normal bacteria were then cultured for 3h in 8-well glass bottom μ-slides (Ibidi). For persister enriched bacteria, biofilms were subjected to fresh medium containing 0, 0.25, 2.5, 5 or 25 mg/L Ciprofloxacin for 24 hours, 37°C. The bacterial solutions were then discarded and fresh media containing 0, 25, 50, 100 or 200 μM of the AMP was added to each well.

Both normal and persister enriched biofilms were cultured for 2 or 24 hours (37°C) before washed twice in PBS and stained using LIVE/DEAD BacLight according to the manufacturer (Thermo Fisher Scientific). Viability was studied using a wide field fluorescence microscope (Zeiss). Three independent experiments were performed.

Morphology studies

Normal as well as persister biofilms exposed to 0, 25, 50, 100 or 200 μM AMP were produced as described above and then fixed in 4% buffered formaldehyde overnight in room temperature. The samples were rinsed three times in PBS and subjected to a drying gradient, 50, 60, 70, 80 90 and 100% ethanol for ten minutes per step. Then samples were subjected to 50% hexamethylsilazane in ethanol for 20 minutes and left in 100% hexamethylsilazane until dry after evaporation in ambient air. Samples were gold sputtered for 60s, 10 mA, and studied in SEM (Leo Ultra 55).

Results

MIC determination and planktonic persister formation

Minimum inhibitory concentration of Ciprofloxacin for S. epidermidis 35984 was determined to 0.25 mg/L by visual inspection. This concentration gave the first clear test tube in the antibiotic gradient tested, and all antibiotic concentrations lower than this produced visual bacterial growth.

Stationary phase bacteria are known to produce the most persister cells [10]. When planktonic stationary phase bacteria were exposed to Ciprofloxacin in concentration of the MIC value (0.25 mg/L), 10, 20 and 100 times the MIC, and cultured on agar plates, a small but significant bacterial population was noted, as seen in Figure 1. Only persister cells survive these high antibiotic concentrations [11]. When using 5 mg/L Ciprofloxacin, i.e. 20 times the MIC value, there was an average of 1200 ± 300 CFU/ml left when plated, 0.02% of the total population or a 4-log reduction.